DMAC vs DOCU · $157.4M cap vs P/E 15, rev $2.98B
DiaMedica Therapeutics Inc (DMAC) versus DocuSign Inc (DOCU) — a side-by-side from cached financials, not a winner call.
DiaMedica Therapeutics Inc (DMAC) is a biotechnology company listed on US.
DocuSign Inc (DOCU) is a software - application company listed on US.
DMAC does not have a complete income-statement cache yet.
Latest reported DOCU revenue for 2025-01-31 was $2.98B. Net income was $1.07B. Revenue was up 7.8% from 2024-01-31 to 2025-01-31. DOCU currently screens at market cap $15.74B and trailing P/E 14.8.
DMAC currently screens at market cap $157.4M. DOCU currently screens at market cap $15.74B and trailing P/E 14.8.
Not investment advice. Open the DMAC and DOCU stock pages for the full models.
Not investment advice.